Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Perez, Edith A., Dueck, Amylou C., McCullough, Ann E., Reinholz, Monica M., Tenner, Kathleen S., Davidson, Nancy E., Gralow, Julie, Harris, Lyndsay N., Kutteh, Leila A., Hillman, David W., Jenkins, Robert B., Chen, Beiyun
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2012
Matèries:
Brief Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3260130/
https://ncbi.nlm.nih.gov/pubmed/22138096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djr490
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars